CD33 and acute myeloid leukemia: Myeloid leukemias are likewise an active arena: NKG2D-ligand–redirected, membrane-bound IL-15 CAR-NK cells produced a 67% complete response rate in relapsed/refractory AML (NCT04623944), and a separate phase 1 study of CD33-targeted CAR-NK cells reported a favorable safety profile—with cytokine release syndrome in only 1 of 10 patients—and molecular remission in 60% of treated individuals (NCT05008575) (71, 72).